Fei Shen

Fei Shen has held various roles in the biopharmaceutical industry since 2007. Fei began their career as a Scientist in the Pharmacology Department at Theravance Biopharma US, Inc., and was subsequently promoted to Research Scientist and Senior Scientist. In 2015, they joined Boehringer Ingelheim as Head of In Vivo Pharmacology, Immunology & Respiratory Research, and was later promoted to Investment Director and Managing Director of the Boehringer Ingelheim Venture Fund USA Inc. In 2020, they joined Rgenta Therapeutics Inc. as a Board of Directors member and Observer of the Board of Directors. In 2021, they became a Co-Founder and Board of Directors member of ArrePath, and also joined the Board of Directors of STRM.BIO.

Fei Shen obtained a B.S. in Biochemistry from East China University of Science and Technology in 1999, followed by an M.S. in Neuroscience from Eastern Illinois University in 2002. In 2007, they obtained a Ph.D. in Neuropharmacology from Loyola University Chicago Stritch School of Medicine.